NO2972131T3 - - Google Patents

Info

Publication number
NO2972131T3
NO2972131T3 NO14719160A NO14719160A NO2972131T3 NO 2972131 T3 NO2972131 T3 NO 2972131T3 NO 14719160 A NO14719160 A NO 14719160A NO 14719160 A NO14719160 A NO 14719160A NO 2972131 T3 NO2972131 T3 NO 2972131T3
Authority
NO
Norway
Application number
NO14719160A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2972131(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2972131T3 publication Critical patent/NO2972131T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO14719160A 2012-09-11 2014-03-13 NO2972131T3 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11

Publications (1)

Publication Number Publication Date
NO2972131T3 true NO2972131T3 (pt) 2018-04-21

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14719160A NO2972131T3 (pt) 2012-09-11 2014-03-13

Country Status (32)

Country Link
US (6) US20140072560A1 (pt)
EP (1) EP2895188B1 (pt)
JP (3) JP2015533797A (pt)
KR (2) KR102133699B1 (pt)
CN (2) CN110051823A (pt)
AR (1) AR092532A1 (pt)
AU (2) AU2013315750B9 (pt)
BR (1) BR112015005161A2 (pt)
CA (1) CA2882551A1 (pt)
CL (1) CL2015000572A1 (pt)
CO (1) CO7400876A2 (pt)
CY (1) CY1120062T1 (pt)
DK (1) DK2895188T3 (pt)
DO (1) DOP2015000055A (pt)
EA (1) EA031324B1 (pt)
EC (1) ECSP15014138A (pt)
ES (1) ES2657377T3 (pt)
HR (1) HRP20180182T1 (pt)
HU (1) HUE036524T2 (pt)
IL (2) IL237311B (pt)
IN (1) IN2015KN00452A (pt)
LT (1) LT2895188T (pt)
MX (2) MX360044B (pt)
NO (1) NO2972131T3 (pt)
PE (2) PE20150996A1 (pt)
PL (1) PL2895188T3 (pt)
PT (1) PT2895188T (pt)
RS (1) RS57013B1 (pt)
SG (1) SG11201501460RA (pt)
SI (1) SI2895188T1 (pt)
TW (2) TWI609877B (pt)
WO (1) WO2014043103A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
ES2734070T3 (es) 2011-10-18 2019-12-04 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con iones de magnesio
KR102133699B1 (ko) * 2012-09-11 2020-07-14 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
MX2016016318A (es) * 2014-06-13 2017-06-12 Lupin Atlantis Holdings Sa Proceso para la purificacion de la proteina de fusion.
EP2975050B1 (en) * 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
KR102018608B1 (ko) * 2014-12-31 2019-09-06 주식회사 엘지화학 목적하는 함량으로 불순물을 포함하는 TNFR-Fc 융합 단백질의 제조방법
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
RU2018121653A (ru) * 2015-11-18 2019-12-19 Мерк Патент Гмбх Улучшенное разделение белков при ионообменной хроматографии
CA3005484A1 (en) * 2015-11-18 2017-05-26 Merck Patent Gmbh Opposite ph-salt gradients for improved protein separations
AU2017286676B2 (en) * 2016-06-17 2024-07-25 F. Hoffmann La-Roche Ag Purification of multispecific antibodies
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
CN110582510B (zh) * 2017-03-24 2023-09-15 科学与工业研究委员会 用于纯化重组抗体片段的方法
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
AU2022236913A1 (en) * 2021-03-16 2023-10-26 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
ES2251009T3 (es) 1990-06-28 2006-04-16 Sanofi-Aventis Deutschland Gmbh Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso.
CA2123593C (en) 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
BR0108193A (pt) 2000-02-10 2003-02-25 Wyeth Corp Processo para tratamento ou inibição de dano celular ou morte celular
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
ES2370235T3 (es) 2001-02-23 2011-12-13 Immunex Corporation Recuperación eficaz de proteínas replegadas correctamente.
DK1946776T3 (en) 2002-02-27 2017-03-13 Immunex Corp STABILIZED TNFR-FC COMPOSITION COMPREHENSIVE ARGININE
ATE464043T1 (de) * 2002-08-22 2010-04-15 Vasopharm Biotech Gmbh Pharmazeutische zusammensetzung enthaltend l- arginin
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
CA2515539A1 (en) 2003-02-28 2004-09-10 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
JPWO2004082715A1 (ja) 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
CA2533796A1 (en) 2003-08-01 2005-02-10 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
CN102020697B (zh) 2003-10-14 2014-10-29 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
US7750129B2 (en) * 2004-02-27 2010-07-06 Ge Healthcare Bio-Sciences Ab Process for the purification of antibodies
WO2005082377A1 (ja) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
CN1930281A (zh) 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
EP1908482B1 (en) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
SG153832A1 (en) 2005-12-20 2009-07-29 Bristol Myers Squibb Co Stable protein formulations
AU2006330858A1 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
CA2665567C (en) 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
CL2007002881A1 (es) 2006-10-20 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
WO2008079290A2 (en) 2006-12-21 2008-07-03 Amgen Inc Stable buffered formulations containing polypeptides
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CN101679941A (zh) 2007-03-02 2010-03-24 惠氏公司 在细胞培养物中使用铜和谷氨酸盐生产多肽
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
HUE041555T2 (hu) 2007-06-14 2019-05-28 Biogen Ma Inc Natalizumab antitest készítmények formulációk
NZ622583A (en) 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
CA2717129A1 (en) * 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
JP5677943B2 (ja) * 2008-06-05 2015-02-25 アフィボディ・アーベーＡｆｆｉｂｏｄｙ Ａｂ ポリペプチド
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
CN102574911B (zh) 2009-08-07 2017-06-06 Emd密理博公司 从样品的一或多种杂质中纯化靶蛋白的方法
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
MX2012012526A (es) 2010-04-26 2012-11-23 Novartis Ag Medio de cultivo celular mejorado.
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
US20130209465A1 (en) 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
SG187885A1 (en) 2010-08-31 2013-03-28 Friesland Brands Bv Culture medium for eukaryotic cells
EP2627425A4 (en) * 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
ES2759931T3 (es) 2011-04-20 2020-05-12 Sandoz Ag Formulaciones líquidas farmacéuticas estables de la proteína de fusión TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2013006454A1 (en) * 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use
HUE033279T2 (en) 2011-07-01 2017-11-28 Amgen Inc Mammalian cell culture
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
ES2651483T3 (es) * 2011-08-17 2018-01-26 Ares Trading S.A. Método para preparar la forma activa de la proteína de fusión TNRF-Fc
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
ES2734070T3 (es) * 2011-10-18 2019-12-04 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con iones de magnesio
EA029193B1 (ru) * 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
KR102133699B1 (ko) * 2012-09-11 2020-07-14 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
CA2916836C (en) * 2014-07-31 2017-12-12 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
PL2895188T3 (pl) 2018-06-29
ES2657377T3 (es) 2018-03-05
CN110051823A (zh) 2019-07-26
IL267452B (en) 2021-05-31
EP2895188A1 (en) 2015-07-22
DOP2015000055A (es) 2015-04-30
US20190300602A1 (en) 2019-10-03
US10947306B2 (en) 2021-03-16
JP6913066B2 (ja) 2021-08-04
AU2018247244A1 (en) 2018-11-01
AR092532A1 (es) 2015-04-22
RS57013B1 (sr) 2018-05-31
ECSP15014138A (es) 2016-01-29
TWI716649B (zh) 2021-01-21
US11001627B2 (en) 2021-05-11
SI2895188T1 (en) 2018-05-31
CA2882551A1 (en) 2014-03-20
CO7400876A2 (es) 2015-09-30
TW201803593A (zh) 2018-02-01
IL237311A0 (en) 2015-04-30
MX2018012749A (es) 2020-11-12
US20140072560A1 (en) 2014-03-13
MX2015003090A (es) 2015-07-14
SG11201501460RA (en) 2015-04-29
KR102250937B1 (ko) 2021-05-12
US20190300601A1 (en) 2019-10-03
US20190300600A1 (en) 2019-10-03
JP2021100929A (ja) 2021-07-08
US10954294B2 (en) 2021-03-23
IL267452A (en) 2019-08-29
EA201590542A1 (ru) 2015-07-30
DK2895188T3 (en) 2018-02-26
IN2015KN00452A (pt) 2015-07-17
CN104902914B (zh) 2019-01-01
PE20150996A1 (es) 2015-08-01
TW201425331A (zh) 2014-07-01
JP2019038817A (ja) 2019-03-14
PE20200607A1 (es) 2020-03-10
MX360044B (es) 2018-10-19
AU2013315750B9 (en) 2018-11-15
HRP20180182T1 (hr) 2018-04-20
US10954295B2 (en) 2021-03-23
US20180037642A1 (en) 2018-02-08
KR20150056601A (ko) 2015-05-26
PT2895188T (pt) 2018-02-08
AU2018247244B2 (en) 2020-05-28
AU2013315750A1 (en) 2015-03-05
CL2015000572A1 (es) 2016-02-05
KR102133699B1 (ko) 2020-07-14
WO2014043103A1 (en) 2014-03-20
HUE036524T2 (hu) 2018-07-30
EA031324B1 (ru) 2018-12-28
US10954293B2 (en) 2021-03-23
AU2013315750B2 (en) 2018-07-12
CY1120062T1 (el) 2018-12-12
IL237311B (en) 2019-07-31
LT2895188T (lt) 2018-04-10
US20190330325A1 (en) 2019-10-31
JP2015533797A (ja) 2015-11-26
TWI609877B (zh) 2018-01-01
EP2895188B1 (en) 2017-11-15
KR20200085937A (ko) 2020-07-15
CN104902914A (zh) 2015-09-09
EP2895188A4 (en) 2016-05-25
BR112015005161A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
BR112014017614A2 (pt)
BR112014017592A2 (pt)
BR112014017659A2 (pt)
BR112014017744A2 (pt)
BR112014017646A2 (pt)
AR092201A1 (pt)
BR112014017607A2 (pt)
BR112013027865A2 (pt)
BR112014017609A2 (pt)
BR112014018800A2 (pt)
BR112014017647A2 (pt)
BR112014019572A2 (pt)
BR112014017618A2 (pt)
BR112014013184A8 (pt)
BR112014017621A2 (pt)
BR112014020279A2 (pt)
BR112014019799A2 (pt)
BR112014019213A2 (pt)
BR112014019189A2 (pt)
BR112014017667A2 (pt)
BR112014018093A2 (pt)
BR112014024781A2 (pt)
BR112014020239A2 (pt)
BR112014017600A2 (pt)
BR112014017596A2 (pt)